Page 1 | Search Results | Blood Advances | American Society of Hematology

Skip Nav Destination

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel

Nausheen Ahmed, William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Jamie Brower, Gunjan L Shah, Andy I. Chen, Olalekan O. Oluwole, Stephen J. Schuster, Michael R Bishop, Joseph P. McGuirk, Peter A. Riedell

Blood Adv bloodadvances.2023012549.

https://doi.org/10.1182/bloodadvances.2023012549

Published: 2024

Includes: Supplemental data

Journal Articles

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

Armin Ghobadi, Javier Munoz, Jason R. Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel-Angel Perales, Patrick M. Reagan, Joseph McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O. Oluwole

Blood Adv (2024) 8 (11): 2982–2990.

https://doi.org/10.1182/bloodadvances.2023011532

Published: 2024

Includes: Supplemental data

Journal Articles

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Blood Adv (2023) 7 (18): 5579–5585.

https://doi.org/10.1182/bloodadvances.2023010302

Published: 2023

Includes: Supplemental data

Journal Articles

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Shakthi T. Bhaskar, Vivek G. Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy I. Chen, Veronika Bachanova, Joseph E. Maakaron, Peter A. Riedell, Olalekan O. Oluwole

Blood Adv (2023) 7 (17): 4765–4772.

https://doi.org/10.1182/bloodadvances.2022008937

Published: 2023

Journal Articles

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Kitsada Wudhikarn, Ana Alarcon Tomas, Jessica R. Flynn, Sean M. Devlin, Jamie Brower, Veronika Bachanova, Loretta J. Nastoupil, Joseph P. McGuirk, Richard T. Maziarz, Olalekan O. Oluwole, Stephen J. Schuster, David L. Porter, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales

Blood Adv (2023) 7 (13): 3192–3198.

https://doi.org/10.1182/bloodadvances.2022008294

Published: 2023

Includes: Supplemental data

Journal Articles

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, Patrick M. Reagan, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, Michael Crump, John Kuruvilla, Eric Van Den Neste, Umar Farooq, Lynn Navale, Venita DePuy, Jenny J. Kim, Christian Gisselbrecht

Blood Adv (2021) 5 (20): 4149–4155.

https://doi.org/10.1182/bloodadvances.2020003848

Published: 2021

Includes: Supplemental data

Journal Articles

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos, Armin Ghobadi, Olalekan O. Oluwole, Patrick M. Reagan, Lazaros J. Lekakis, Yi Lin, Marika Sherman, Marc Better, William Y. Go, Jeffrey S. Wiezorek, Allen Xue, Adrian Bot

Blood Adv (2020) 4 (19): 4898–4911.

https://doi.org/10.1182/bloodadvances.2020002394

Published: 2020

Includes: Supplemental data

NARROW

Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only